MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ and TASE: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
CORRECTION of pre-IND meeting for treprostinil in June 2017
Actor Paul Sparks speaks to Congress about diabetes. Click here for the video.
|Aug 07, 2017||MannKind Corporation Reports 2017 Second Quarter Financial Results… More|
|Aug 07, 2017||MannKind and One Drop Partner to Launch the A-ONE Clinical Trial… More|
|Jul 25, 2017||MannKind Corporation to Hold 2017 Second Quarter Financial Results Conference Call on August 7, 2017… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.